Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Phase 2

Terminated

Conditions: Hemophilia A With Inhibitors
Hemophilia B With Inhibitors

Interventions: Drug: CSL689
Drug: Eptacog alfa (activated)

First Posted Date: 2015-06-29

Last Posted Date: 2019-08-28

Lead Sponsor: CSL Behring

Target Recruit Count: 25

Registration Number: NCT02484638

Locations: 🇬🇪
Site Reference # 2680001, Tbilisi, Georgia
🇮🇹
Site Reference # 3800023, Milano, Italy
🇲🇾
Site Reference # 4580001, Kuala Lumpur, Malaysia

and more 7 locations

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

Phase 1

Completed

Conditions: Congenital Coagulation Factor VII Deficiency

Interventions: Biological: Eptacog alfa (activated) or pdFVII
Biological: CSL689

First Posted Date: 2015-06-12

Last Posted Date: 2017-04-26

Lead Sponsor: CSL Behring

Target Recruit Count: 9

Registration Number: NCT02470871

Locations: 🇳🇱
Site Reference 5280023, Njmegen, Netherlands
🇳🇴
Site Reference # 5780001, Oslo, Norway

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

Completed

Conditions: Congenital Fibrinogen Deficiency

Interventions: Biological: FCH

First Posted Date: 2015-04-27

Last Posted Date: 2018-01-17

Lead Sponsor: CSL Behring

Target Recruit Count: 22

Registration Number: NCT02427217

Locations: 🇨🇦
Study Site, Montreal, Quebec, Canada

A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment

Phase 1

Completed

Conditions: Acute Myocardial Infarction

Interventions: Biological: CSL112
Other: Placebo

First Posted Date: 2015-04-27

Last Posted Date: 2017-09-19

Lead Sponsor: CSL Behring

Target Recruit Count: 32

Registration Number: NCT02427035

Locations: 🇩🇪
Study Site - 17101, Berlin, Germany
🇩🇪
Study Site - 17102, Munich, Germany
🇬🇧
Study Site - 24101, London, United Kingdom

and more 1 locations

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

Phase 1

Completed

Conditions: Hemophilia B

Interventions: Genetic: AAV5-hFIX

First Posted Date: 2015-03-24

Last Posted Date: 2022-06-27

Lead Sponsor: CSL Behring

Target Recruit Count: 10

Registration Number: NCT02396342

Locations: 🇳🇱
uniQure Investigative Site, Utrecht, Netherlands

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

Completed

Conditions: Hemorrhage

Interventions: Biological: Kcentra®
Biological: Plasma

First Posted Date: 2014-12-18

Last Posted Date: 2021-05-26

Lead Sponsor: CSL Behring

Target Recruit Count: 2238

Registration Number: NCT02319460

Locations: 🇺🇸
Study Site, Oakland, California, United States

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Phase 3

Completed

Conditions: Hereditary Angioedema Types I and II

Interventions: Biological: C1-esterase inhibitor

First Posted Date: 2014-12-12

Last Posted Date: 2018-11-14

Lead Sponsor: CSL Behring

Target Recruit Count: 126

Registration Number: NCT02316353

Locations: 🇬🇧
Study Site, London, United Kingdom

Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects

Phase 3

Completed

Conditions: Acute Major Bleeding
Reversal of Coagulopathy

Interventions: Biological: BE1116 (Prothrombin Complex Concentrate)

First Posted Date: 2014-11-02

Last Posted Date: 2016-05-04

Lead Sponsor: CSL Behring

Target Recruit Count: 11

Registration Number: NCT02281201

Locations: 🇯🇵
Nippon Medical School Hospital, Sendagi, Bunkyo, Japan
🇯🇵
Kyushu Medical Center, Chuo-ku, Fukuoka, Japan
🇯🇵
Nippon Medical School Chiba Hokusoh Hospital, Kamagari, Inzai, Japan

and more 8 locations

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

Phase 3

Completed

Conditions: Severe Hemophilia A
Hemophilia A

Interventions: Biological: rVIII-SingleChain

First Posted Date: 2014-06-24

Last Posted Date: 2021-10-27

Lead Sponsor: CSL Behring

Target Recruit Count: 246

Registration Number: NCT02172950

Locations: 🇺🇸
Study Site 8400213, San Diego, California, United States
🇺🇸
Study Site 8400241, Aurora, Colorado, United States
🇺🇸
Study Site 8400118, Hartford, Connecticut, United States

and more 61 locations

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Phase 2

Completed

Conditions: Acute Myocardial Infarction

Interventions: Biological: CSL112
Biological: Placebo

First Posted Date: 2014-04-09

Last Posted Date: 2021-03-15

Lead Sponsor: CSL Behring

Target Recruit Count: 1267

Registration Number: NCT02108262

Locations: 🇺🇸
Study Site 16101, Birmingham, Alabama, United States
🇺🇸
Study Site 16078, Huntsville, Alabama, United States
🇺🇸
Study Site - 16168, Concord, California, United States

and more 186 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy